Key strategies for a successful European drug launch
We recently hosted a webinar focused on essential strategies for launching orphan drugs successfully in the European market. Our latest whitepaper brings you the key takeaways.
Our expert panel included, Raymond A. Huml, Vice President of Rare Strategy at Sciensus, and Andrew Cummins, Vice President of Business Development at Sciensus, along with Kirsty Hoyle, CEO of Metabolic Support UK.
The session examined the complexities involved in bringing a new product to market in Europe and highlighted how pharma and biotech companies can navigate these challenges to achieve success. Expert panellists discussed various partnership models aligned with different organisational objectives, and the growing impact of digital technologies in enhancing patient access and adherence.
The conversation also underscored the critical contribution of patient advocacy groups, the importance of early stakeholder engagement, and the need to prioritise equity, diversity, and inclusion throughout the launch process.
Webinar insights: strategic planning for drug launches in Europe
In this paper we cover how to:
- Navigate European regulatory hurdles effectively
- Choose the right partnership for your organisation
- Engage early with patient advocacy groups to drive success
- Leverage digital innovation to improve patient access and treatment adherence for orphan drugs
- Prioritise equity, diversity, and inclusion when launching a new orphan drug in Europe
Download this free paper for strategic insights on launching orphan drugs in Europe.
Our Sciensus expert speakers
About Sciensus
Sciensus is a proven life sciences solutions partner with more than 30 years’ experience in navigating and unlocking the complex European healthcare ecosystem to maximise patient reach. We help accelerate the development journey, bringing medicines into the market and directly to patients to improve health outcomes. Through cutting-edge patient engagement programmes, offering an exclusive combination of skilled in-person care and digital support, we help patients make the most of their treatment and generate real-world evidence that can be used to improve treatment pathways.